Stock A086890 ISU ABXIS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials ISU Abxis Co., Ltd.

Equities

A086890

KR7086890001

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
6,850 KRW +1.78% Intraday chart for ISU Abxis Co., Ltd. -2.97% +13.22%
2023 ISU Abxis Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
2022 Eucure Biopharma Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025
Capitalization 1 291,676 190,800 209,398 241,840 -
Enterprise Value (EV) 2 291.7 190.8 209.4 185 180.2
P/E ratio 338 x - - 30.3 x 20.6 x
Yield - - - - -
Capitalization / Revenue - 4.63 x 3.86 x 3.39 x 2.85 x
EV / Revenue - 4.63 x 3.86 x 2.6 x 2.12 x
EV / EBITDA - - - 9.92 x 7.8 x
EV / FCF - - - 41.1 x 24 x
FCF Yield - - - 2.43% 4.16%
Price to Book - - - 2.79 x 2.46 x
Nbr of stocks (in thousands) 33,183 33,183 34,611 35,305 -
Reference price 3 8,790 5,750 6,050 6,850 6,850
Announcement Date 3/17/22 3/9/23 3/14/24 - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025
Net sales 1 - 41.17 54.31 71.3 85
EBITDA 1 - - - 18.65 23.1
EBIT 1 - -16.03 3.886 9.2 13.6
Operating Margin - -38.94% 7.16% 12.9% 16%
Earnings before Tax (EBT) 1 - - - 8.4 12.4
Net income 1 0.8299 - - 7.85 11.55
Net margin - - - 11.01% 13.59%
EPS 2 26.00 - - 226.4 333.0
Free Cash Flow 3 - - - 4,500 7,500
FCF margin - - - 6,311.36% 8,823.53%
FCF Conversion (EBITDA) - - - 24,128.69% 32,467.53%
FCF Conversion (Net income) - - - 57,324.84% 64,935.06%
Dividend per Share - - - - -
Announcement Date 3/17/22 3/9/23 3/14/24 - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales - 0.1827 0.1896 0.1998
EBITDA - - - -
EBIT 1 0.0267 0.0397 0.0394 0.0418
Operating Margin - 21.73% 20.78% 20.92%
Earnings before Tax (EBT) - - - -
Net income - - - -
Net margin - - - -
EPS - - - -
Dividend per Share - - - -
Announcement Date - - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025
Net Debt 1 - - - - -
Net Cash position 1 - - - 56.8 61.6
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 2 - - - 4,500 7,500
ROE (net income / shareholders' equity) - - - 9.65% 12.7%
ROA (Net income/ Total Assets) - - - 3.7% 5.15%
Assets 1 - - - 212.2 224.3
Book Value Per Share 3 - - - 2,457 2,790
Cash Flow per Share 3 - - - 474.0 605.0
Capex 1 - - - 3.5 3.75
Capex / Sales - - - 4.91% 4.41%
Announcement Date 3/17/22 3/9/23 3/14/24 - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6,850 KRW
Average target price
8,000 KRW
Spread / Average Target
+16.79%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
ISU ABXIS CO., LTD. Stock ISU Abxis Co., Ltd.
+13.22% 175M
CSL LIMITED Stock CSL Limited
-3.93% 86.16B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 40.17B
BIOGEN INC. Stock Biogen Inc.
-16.48% 31.47B
UCB Stock UCB
+54.88% 25.24B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-13.58% 15.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.12% 11.96B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.56% 11.61B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.62% 8.84B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-2.11% 7.93B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A086890 Stock
  4. Financials ISU Abxis Co., Ltd.